
|Videos|October 7, 2016
Scrutiny of High Drug Costs Require Specialty Pharmacy Strategy Shift
Author(s)Lauren Santye, Assistant Editor
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.
Advertisement
Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how specialty pharmacies may need to alter current strategies with increasing attention on high drug costs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
2
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
3
Doxecitine–Doxribtimine Becomes First Approved Treatment for Rare Genetic Disorder
4
RSV May Complicate Multiple Myeloma Care Through Therapy Delays, Not Mortality Risk
5














































































































































































































